A global biopharma company focusing on creating value for people living with neurology and immunology diseases.
We are inspired by patients, driven by science.
Ahead of the 15th
#ImmunologySummit
, we’re looking back on some memories shared by previous delegates.
From plenaries showcasing the latest clinical innovations to unparalleled networking opportunities, we're proud to serve the immunology community with each edition.
🌟 Together, we hope to achieve more! 🌟 We partner with
@ClearPointNeuro
as we share a dedication to innovation in the neurology space. You can read more here
#Collaboration
At UCB, we’re committed to improving quality of life for those living with
#RareDiseases
like
#MyastheniaGravis
(MG).
Listening to those living with MG helps us better identify and address unmet needs.
Read more in Manuela’s
@PharmaTimes
piece:
At UCB, we believe that everyone living with
#epilepsy
should understand their risk of Sudden Unexpected Death in Epilepsy (SUDEP).
Hear from Andrea Wilkinson about our commitment to understanding SUDEP.
#SUDEPActionDay
Today is
#SUDEPActionDay
! Together, we can raise awareness about Sudden Unexpected Death in Epilepsy (SUDEP), empowering those living with
#epilepsy
to understand their risks, tackle unmet needs and take the necessary actions to live more safely.
#OurRisksOurRights
Learn
We’re excited to join leading research scientists this week at
#AANEM2024
as we present our latest research and innovations!
With focus and care, we hope to come together to create real change and improvements for people with
#MG
.
Learn more:
As we gather at this year’s
#AANEM2024
we look forward to discussing the latest scientific advances in
#MyastheniaGravis
(MG) and providing new insights on treatment management to benefit the quality of life of those living with MG.
Learn more about MG here:
For healthcare professionals only.
👏 A successful Pre-Congress Day at FFN EU 2024!
Co-chairs Prof Kassim Javaid and Mr Andrew Gray led discussions on a multidisciplinary approach to secondary fracture prevention. Continue the conversation with our podcast:
FOR MEDIA: UCB showcases extensive data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
Read more:
For healthcare professionals only.
🚀 Today kicks off the FFN European Congress 2024! We're looking forward to the pre-congress day session on post-fracture care, highlighting available resources through the FLS Academy & Network.
👉
Great news from Rwanda 🇷🇼, where one of our antiseizure medicines is now publicly available and reimbursed. 💊
A step forward in our commitment to making a difference for people with epilepsy in underserved communities. 🌍
Read more:
#epilepsy
From manufacturing challenges to evolving regulations, cell and gene therapy (CGT) development is anything but simple. Discover how we can navigate these challenges in an interview with Clinical Leader and UCB’s Head of US Research, Roger Palframan here:
Our participation in the Landmark study underscores UCB's commitment to elevating the care for those living with
#Parkinson
's. With the help of cutting-edge technology and our partners, we aim to gather new insights into this condition.
Learn more:
Since 2010 we’ve welcomed 6,500+ delegates from 63 countries to the
#ImmunologySummit
.
The Summit is an important part of our long-term commitment to driving innovation in patient care and we look forward to uniting the community for the 15th anniversary in Prague this November.
FOR MEDIA: The U.S.
#FDA
has approved a new treatment option for adults with active
#PsA
, adults with active
#nr
-axSpA with objectives signs of inflammation, and adults with active
#AS
.
Find out more:
Our gene therapy collaboration with
@KU_Leuven
is built on trust. Through open dialogue & mutual respect, we've built a foundation that empowers us to tackle complex challenges together. This fuels a shared mission of driving impact in healthcare innovation. Learn more here